BeOne showcases landmark phase 3 data in CLL patients aged 80+ at EHA 2026, reinforcing Brukinsa benefit

BeOne Medicines Ltd., a global oncology company, announced the presentation of a large phase 3 dataset in patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged